Target family: Neuropeptide FF/neuropeptide AF receptors (type: gpcr)
Target: NPFF2 receptor

Ligand: neuropeptide FF (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.699999809265137 pKi
Reference (Journal): Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands.
Published in: Neuroscience

Ligand: neuropeptide FF (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.699999809265137 pKi
Reference (Journal): Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226.
Published in: Br J Pharmacol

Ligand: EFWSLAAPQRF-NH2 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.6 pKi
Reference (Journal): Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists.
Published in: Eur J Pharmacol

Ligand: dNPA (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 10.569999694824219 pKi
Reference (Journal): Anti-analgesia of a selective NPFF2 agonist depends on opioid activity.
Published in: Biochem Biophys Res Commun

Ligand: compound 46 [PMID: 25268943] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pKi
Reference (Journal): Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors.
Published in: J Med Chem

Ligand: BIBP3226 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Identification and characterization of two G protein-coupled receptors for neuropeptide FF.
Published in: J Biol Chem

Ligand: BIBP3226 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Agonist and antagonist activities on human NPFF(2) receptors of the NPY ligands GR231118 and BIBP3226.
Published in: Br J Pharmacol

Ligand: AC263093 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Neuropeptide FF receptors have opposing modulatory effects on nociception.
Published in: J Pharmacol Exp Ther

Ligand: 1DMe (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands.
Published in: Neuroscience

Ligand: 1DMe (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Identification and characterization of two G protein-coupled receptors for neuropeptide FF.
Published in: J Biol Chem

Ligand: 1DMe (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists.
Published in: Eur J Pharmacol